Back to the main directory
EarningsReview / Equity
- The sun is still shining by BNP Paribas Exane
- JNCE: 3Q18 Update: Pipeline Progress and Incremental Data Supporting JTX-2011 by Raymond James
- Continuing to build revenues by BNP Paribas Exane
- Vivendi: A Star Is (re-)Born, Reiterate Outperform with TP of €25 by Raymond James
- WMT: Reaffirm Outperform and $105 Target; F3Q19 U.S. Comps & Adj. EPS Beat by Raymond James
- FBK: Expanding TN Footprint, Entering GA Through Branch Acquisition by Raymond James
- SFNC: Takeaways From Reliance Bank Acquisition Call; Maintain Market Perform by Raymond James
- SONO: F4Q Results: Profitable Growth, It’s What'cha, What'cha, What'cha Want by Raymond James
- WSM: F3Q18: Sales Miss; EPS In-Line; Reaffirm Market Perform by Raymond James
- Preview of Safran''s CMD on November 29 by BNP Paribas Exane
- Under New Management: Outperform by BNP Paribas Exane
- Chemring: A Post-YE Statement with Volatile Ingredients by Raymond James
- Show me the Value (Floor) by BNP Paribas Exane
- Now de-risked enough? by BNP Paribas Exane
- Q3 18 surprises on orders and portfolio reshuffle by BNP Paribas Exane
- INVEST SECURITIES - Vivendi : Un peu de patience - ACHAT, OC 25,3€ by Invest Securities
- Henkel: Top Line Likely to Remain Soft - Market Perform Reiterated by Raymond James
- Seafood - The Fat Trout Weekly by DnB Markets
- ODDO BHF Small & MIDCAP MORNING NEWS - 16/11/2018 by Oddo BHF
- ACBI: Upgrade to Outperform - Management Gets Back to Basics with Tennessee Divestiture by Raymond James
- ODDO BHF Small & MIDCAP MORNING NEWS - 11/16/2018 by Oddo BHF
- Humana (Buy, TP: SEK73.00) - FCF generation re-established by DnB Markets
- Investments and a warning by DnB Markets
- Results broadly in line, fairly valued by BNP Paribas Exane
- Swedish Orphan Biovitrum (Buy, TP: SEK330.00) - Truly transformative by DnB Markets